Shares in Arca Biopharma Inc. were soaring in early Thursday trading after the biotech reported that one of its treatments for cardiovascular disease has been issued a patent in Europe.
The Westminster biotech reported that the European patent was validated in: Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland and the United Kingdom.
Shares in Arca Biopharma (Nasdaq: ABIO) were up more than 30 percent in early Thursday trading, rising 37 cents to $1.55.
The company said that its patent for its treatment of "cardiovascular disease and conditions with a thiol-substituted isosorbide mononitrate based on genetic targeting" is pending in the U.S.
Read more at the Denver Business Journal: http://bit.ly/2in6Wr3